The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status.
Replication-competent oncolytic viruses hold great potential for the clinical treatment of many cancers. Importantly, many oncolytic virus candidates, such as reovirus and myxoma virus, preferentially infect cancer cells bearing abnormal cellular signaling pathways. Reovirus and myxoma virus are highly responsive to activated Ras and Akt signaling pathways, respectively, for their specificity for viral oncolysis. However, considering the complexity of cancer cell populations, it is possible that other tumor-specific signaling pathways may also contribute to viral discrimination between normal versus cancer cells. Because carcinogenesis is a multistep process involving the accumulation of both oncogene activations and the inactivation of tumor suppressor genes, we speculated that not only oncogenes but also tumor suppressor genes may have an important role in determining the tropism of these viruses for cancer cells. It has been previously shown that many cellular tumor suppressor genes, such as p53, ATM and Rb, are important for maintaining genomic stability; dysfunction of these tumor suppressors may disrupt intact cellular antiviral activity due to the accumulation of genomic instability or due to interference with apoptotic signaling. Therefore, we speculated that cells with dysfunctional tumor suppressors may display enhanced susceptibility to challenge with these oncolytic viruses, as previously seen with adenovirus. We report here that both reovirus and myxoma virus preferentially infect cancer cells bearing dysfunctional or deleted p53, ATM and Rb tumor suppressor genes compared to cells retaining normal counterparts of these genes. Thus, oncolysis by these viruses may be influenced by both oncogenic activation and tumor suppressor status.
Kim
M
M
Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada.
Williamson
C T
CT
Prudhomme
J
J
Bebb
D G
DG
Riabowol
K
K
Lee
P W K
PW
Lees-Miller
S P
SP
Mori
Y
Y
Rahman
M M
MM
McFadden
G
G
Johnston
R N
RN
D000818:Animals; D017209:Apoptosis / Q000235:genetics; D064007:Ataxia Telangiectasia Mutated Proteins; D018797:Cell Cycle Proteins / Q000235:genetics; D045744:Cell Line, Tumor; D004268:DNA-Binding Proteins / Q000172:deficiency / Q000235:genetics; D017353:Gene Deletion; D055785:Gene Knockdown Techniques; D016147:Genes, Tumor Suppressor; D006801:Humans; D051379:Mice; D009233:Myxoma virus / Q000502:physiology*; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology / Q000821:virology*; D050504:Oncolytic Viruses / Q000502:physiology*; D017346:Protein Serine-Threonine Kinases / Q000172:deficiency / Q000235:genetics; D012087:Reoviridae / Q000502:physiology*; D016160:Retinoblastoma Protein / Q000172:deficiency / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000172:deficiency / Q000235:genetics; D056189:Viral Tropism
D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D016160:Retinoblastoma Protein; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; C576325:Atm protein, mouse; D017346:Protein Serine-Threonine Kinases
Mutat Res. 2002 Mar;511(1):45-62
11906841
Cold Spring Harb Symp Quant Biol. 2005;70:99-109
16869743
Cancer Res. 2007 Sep 15;67(18):8818-27
17875723
Semin Cancer Biol. 2003 Aug;13(4):267-73
14563121
J Virol. 2003 May;77(10):5877-88
12719581
Nat Rev Microbiol. 2005 Mar;3(3):201-13
15738948
Cell Cycle. 2004 Aug;3(8):1043-5
15254403
Science. 1996 Oct 18;274(5286):373-6
8832876
Oncogene. 1999 Mar 18;18(11):1935-44
10208415
J Virol. 1996 Jan;70(1):612-6
8523580
Oncogene. 2006 May 18;25(21):3006-22
16501611
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4640-5
16537421
Cancer Cell. 2004 Dec;6(6):611-23
15607965
J Exp Med. 2008 Aug 4;205(8):1929-38
18663127
Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11099-104
15263068
J Virol. 2004 Nov;78(22):12243-51
15507611
Nature. 2003 Jul 31;424(6948):516-23
12872134
Clin Cancer Res. 2008 Nov 1;14(21):7127-37
18981012
J Virol. 1978 Nov;28(2):444-9
214572
Expert Opin Biol Ther. 2007 Sep;7(9):1415-25
17727330
Oncogene. 2007 Jun 14;26(28):4124-34
17213803
Oncogene. 2005 Nov 21;24(52):7817-9
16299540
Leuk Res. 2006 Apr;30(4):449-57
16183118
EMBO J. 1998 Jun 15;17(12):3351-62
9628872
Cancer Gene Ther. 2010 Jan;17(1):69-70
19590528
Cancer Res. 2005 Nov 1;65(21):9982-9990
16267023
Mol Ther. 2008 Mar;16(3):627-32
18253152
Cancer Gene Ther. 2009 Apr;16(4):382
18949012
Arch Virol. 1977;54(4):307-15
562142
Virology. 1993 Nov;197(1):405-11
8212574
J Natl Cancer Inst. 1974 Aug;53(2):347-60
4135597
Blood. 2002 Dec 1;100(12):4146-53
12393565
Science. 1998 Nov 13;282(5392):1332-4
9812900
J Virol. 2009 Jun;83(11):5928-32
19297474
J Biol Chem. 2003 Mar 14;278(11):9309-17
12645530
Drug Discov Today. 2005 Jun 15;10(12):847-55
15970267
Leukemia. 2009 Dec;23(12):2313-7
19865109
Nature. 1994 Sep 1;371(6492):21-2
8072521
Oncogene. 2006 Mar 9;25(10):1509-20
16247442
Mol Ther. 2008 Jan;16(1):52-9
17998900
Blood. 2009 Mar 26;113(13):3059-69
18984860
Hepatology. 2008 Apr;47(4):1136-49
18220274